EUVIMEDEUVIMED entdecken
Crossref

FTY720 increases paclitaxel efficacy in cisplatin‐resistant oral squamous cell carcinoma

Lizeth Andrea Torres Torres, Gabriel Silva, Jovelina Samara Ferreira Alves, Tatiane Resende Ushida, Julia Potenza, Cristiana Bernadelli Garcia, Lucas Oliveira Sousa, Norberto Peporine Lopes, Luciana Oliveira Almeida, Andréia Machado Leopoldino iD

Journal of Oral Pathology & Medicine · 2024

DOI: 10.1111/jop.13498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2024. Verfasst von Lizeth Andrea Torres Torres und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, …. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral squamous cell carcinoma has high recurrence and cisplatin resistance. As cancer stem cells, autophagy, and sphingolipids have been appointed as associated with chemotherapy resistance, we tested combined treatments targeting autophagy and/or sphingolipid metabolism with paclitaxel using cisplatin‐resistant oral squamous cell carcinoma cells.

Methods

Cisplatin‐resistant oral squamous cell carcinoma cells were maintained under exposition to FTY720 and chloroquine combined with paclitaxel and submitted to viability, clonogenicity, and spheres formation assays. The xenograft tumor model using cisplatin‐resistant CAL27 cells was adopted to examine the drug combinations' potential antitumoral efficacy. Using an animal model, sphingolipids profiles from plasma and tissue samples were obtained by liquid chromatography coupled to mass spectrometry to identify potential lipids associated with drug response. Results and Discussion Our results showed higher autophagic flux in cisplatin‐resistant Ooral squamous cell carcinoma (CAL27 and SCC9) cells than in parental cells. The combinations of an autophagy inhibitor (chloroquine) or an autophagy inducer/sphingosine kinase 1 antagonist (FTY720) with paclitaxel (PTX) had a synergistic antitumor effect. Treated CisR cells lost clonogenicity and tumor sphere abilities and reduced proteins associated with proliferation, survival, and cancer stem cells. FTY720 plus PTX had higher antitumor efficacy than PTX against CAL27 CisR xenograft tumor formation. Additionally, increases in glucosylceramide, dehydroglucosylceramide, and sphingomyelin were presented in responsive tumors.

Conclusion

FTY720 sensitizes cisplatin‐resistant oral squamous cell carcinoma cells for paclitaxel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsHead and Neck NeoplasmsAnimalsHumansCisplatinPaclitaxelFingolimod HydrochlorideSquamous Cell Carcinoma of Head and NeckApoptosisSphingolipidsChloroquineCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

autophagycisplatin resistancefingolimodpaclitaxelsphingolipid

Substanzen

CisplatinPaclitaxelFingolimod HydrochlorideSphingolipidsChloroquine

Autor:innen und Institutionen

  • Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
  • NPPNS, Departamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
  • Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.

ORCID-Profile: Andréia Machado Leopoldino

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Universidade de São Paulo

Zitieren

APA

Torres, L. A. T., Silva, G., Alves, J. S. F., Ushida, T. R., Potenza, J., Garcia, C. B., Sousa, L. O., Lopes, N. P., Almeida, L. O., & Leopoldino, A. M. (2024). FTY720 increases paclitaxel efficacy in cisplatin‐resistant oral squamous cell carcinoma. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13498

Vancouver

Torres LAT, Silva G, Alves JSF, Ushida TR, Potenza J, Garcia CB, et al. FTY720 increases paclitaxel efficacy in cisplatin‐resistant oral squamous cell carcinoma. Journal of Oral Pathology & Medicine. 2024. doi:10.1111/jop.13498

BibTeX
@article{Torres2024,
  author = {Torres, Lizeth Andrea Torres and Silva, Gabriel and Alves, Jovelina Samara Ferreira and Ushida, Tatiane Resende and Potenza, Julia and Garcia, Cristiana Bernadelli and Sousa, Lucas Oliveira and Lopes, Norberto Peporine and Almeida, Luciana Oliveira and Leopoldino, Andréia Machado},
  title = {FTY720 increases paclitaxel efficacy in cisplatin‐resistant oral squamous cell carcinoma},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2024},
  doi = {10.1111/jop.13498}
}
Kostenlos starten →